The FDA accepted to review ARIAD Pharmaceuticals� $ARIA New Drug Application (NDA) seeking approval of brigatinib for the treatment of patients with ALK-postive non-small cell lung cancer (NSCLC) who have progressed on crizotinib [Pfizer's $PFE XALKORI]. The agency's action date (PDUFA) is scheduled onApril 29, 2017 under Priority Review status.